Form 4: Xeris Biopharma Holdings CEO John Patrick Shannon Jr. Reports Stock and Derivative Transactions

CEO John Patrick Shannon Jr. reports acquisition of 250,000 shares of common stock and 300,000 stock appreciation rights, along with disposals to cover tax obligations.

Summary

• On August 1, 2024, John Patrick Shannon Jr., CEO of Xeris Biopharma Holdings, acquired 250,000 shares of common stock through a restricted stock unit award.
• He also acquired 300,000 stock appreciation rights (SARs) on the same date.
• The SARs have an exercise price of $2.43 and expire on September 1, 2026, vesting in full on the two-year anniversary of the grant date and will be settled in cash upon exercise.
• The reporting person also acquired 11,037 shares through the Employee Stock Purchase Plan on June 30, 2024.
• Throughout January 2022, 2023 and 2024, shares were withheld by the issuer to cover income tax obligations related to the vesting of restricted stock units (RSUs).
• The reporting of these transactions was delayed due to administrative oversight.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The acquisitions are positive, but the late reporting due to administrative oversight is a concern.

Positives

• The acquisition of 250,000 shares via restricted stock units indicates confidence in the company's future performance.
• The acquisition of 300,000 stock appreciation rights suggests an expectation of future stock price appreciation.

Negatives

• The late reporting of several transactions due to administrative oversight raises concerns about internal controls.
• Shares were withheld by the issuer to cover income tax obligations related to RSU vesting in January of 2022, 2023 and 2024.

Risks

• Administrative oversight leading to late reporting of transactions could indicate weaknesses in internal compliance procedures.
• The value of the stock appreciation rights is dependent on the future performance of the company's stock.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the restricted stock units and stock appreciation rights suggests a multi-year incentive structure for the CEO.

Industry Context

Executive stock ownership and incentive plans are common in the biopharmaceutical industry to align management's interests with those of shareholders. Stock appreciation rights are often used to incentivize executives to increase shareholder value.

Comparison to Industry Standards

• Stock ownership and equity-based compensation are standard practice for CEOs in publicly traded biopharmaceutical companies.
• Companies like Amgen, Gilead, and Biogen also utilize stock options, restricted stock units, and performance-based equity awards to incentivize their executives.
• The vesting schedules and terms of these awards are generally comparable across the industry, with multi-year vesting periods being common.

Stakeholder Impact

• The CEO's increased stock ownership could be viewed positively by shareholders, aligning management's interests with theirs.
• The late reporting of transactions may raise concerns among shareholders regarding the company's internal controls.

Key Dates